All in all, Ingrezza pulled in $2.3 billion in 2024, making for an “all-time record growth year” for the drug, Benevich noted. Teva's Austedo, meanwhile, collected $1.6 billion in sales last year.

William Blair writes that Ingrezza’s 2025 revenue guidance is slightly conservative compared to their 2025 estimate of $2.60 billion and the Street estimate of $2.67 billion, which fell below ...

He emphasized the strong performance of INGREZZA, which is poised for double-digit year-over-year growth despite moderated expectations compared to 2024, the company’s highest growth year to date.

According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for movement disorder tardive dyskinesia). Management proffered guidance for Ingrezza ...

FY25 revenue consensus $2.79B. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock ...

William Blair writes that Ingrezza’s 2025 revenue guidance is slightly conservative compared to their 2025 estimate of $2.60 billion and the Street estimate of $2.67 billion, which fell below investor ...

A quick one on INGREZZA and then on CRENESSITY. Should we expect that 60-40 market share split ... However, early on with a relatively small sample size, so to speak, what we are seeing is ...

Q4 revenue was $627.7 million, slightly below the $629 million estimate. Ingrezza remains the main revenue driver, with a 23% increase in quarterly sales to $615 million. Neurocrine Biosciences ...